Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

This early-phase trial is testing a new drug called HDM2020 in 150 people with advanced squamous non-small cell lung cancer. The drug is designed to target a protein on cancer cells and deliver a chemotherapy agent directly to them. The main goals are to check if the drug is safe…

This early-stage study tests a new drug called HDM2024 in 63 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check if the drug is safe and to see if it can shrink tumors. Participants receive the drug once every three weeks,…

This early-phase study tests a new drug, HDP-101, in Chinese patients with multiple myeloma or similar plasma cell disorders. The goal is to find a safe dose and see if the drug can help control the cancer. About 15 adults who have already tried other treatments will take part.

This study compares a new weekly injection, HDM1005, to the existing drug tirzepatide for weight loss in 372 adults with obesity but without diabetes. Participants receive either HDM1005 or tirzepatide for 52 weeks, plus diet and exercise counseling. The main goal is to measure h…

This Phase 3 trial is testing whether the experimental drug HDM1005 can help people with type 2 diabetes control their blood sugar better than a placebo. About 240 adults who have not used diabetes medication for at least 12 weeks will receive either HDM1005 or a placebo injectio…

This early-phase trial tests an experimental oral drug called HDM2006 in 48 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shows any signs of shrinking tumors. Particip…

This study tests a new drug called HDM1005, given as a weekly injection, to help people with obesity or overweight lose weight. It includes 825 Chinese adults who do not have diabetes. Participants receive either the drug or a placebo for 52 weeks, along with diet and exercise ad…

This early-phase study tests a new drug called HDM2017 in about 96 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants must be 18-75 and …

This study tests a combination of three diabetes drugs (metformin, SGLT-2 inhibitor, and GLP-1 receptor agonist) versus other oral medications in adults with type 2 diabetes who have poor blood sugar control. The goal is to see which combo works better at lowering blood sugar, bl…

This Phase 2 trial is testing an investigational drug called HDM1005 for weight loss in 240 adults with obesity who do not have diabetes. Participants receive weekly injections of either the drug or a placebo for 22 weeks. The main goal is to see how much body weight they lose an…

This study tests a new oral medication, HDM1002, in 360 adults with type 2 diabetes whose blood sugar is not well controlled by diet and exercise alone. Participants will take either a low or high dose of HDM1002 or a placebo daily for 40 weeks. The main goal is to see if the dru…

This study checks whether a single dose of HDM1002 tablets changes the heart's electrical activity (QT interval) in 72 healthy adults aged 18-45. Participants receive the drug, a placebo, and a positive control in random order across four sessions. The goal is to see if the drug …

This study looks at how a new drug called HDM1002 interacts with five common medications (metformin, empagliflozin, midazolam, valsartan, and warfarin) in overweight or obese adults. About 111 healthy participants aged 18-45 with a BMI between 24 and 35 will take these drugs sepa…